ASH 2018 | Midostaurin for newly diagnosed FLT3+ AML: RADIUS-X efficacy and safety data
Midostaurin was the first multikinase inhibitor approved in combination with daunorubicin and cytarabine induction, and high-dose cytarabine (HiDAC) consolidation chemotherapy, for the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, provides updated safety data for midostaurin from the Phase III RADIUS-X trial (NCT02624570). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Perl demonstrates the continued manageable safety profile of midostaurin, with no new safety signals observed.
Get great new content delivered to your inboxSign up